TABLE 1.
Baseline subject characteristics
| Characteristic | Treatment group |
||
|---|---|---|---|
| RV521 350 mg (N = 22) | RV521 200 mg (N = 22) | Placebo (N = 22) | |
| Male, n (%) | 16 (73) | 13 (59) | 15 (68) |
| Ethnicity, n (%) | |||
| Caucasian | 18 (82) | 21 (95) | 21 (95) |
| South Indian | 0 | 0 | 1 (5) |
| Other | 4 (18) | 1 (5) | 0 |
| Age (yrs) | |||
| Mean (SD) | 24.5 (5.50) | 21.7 (3.09) | 24.6 (5.29) |
| Range | 18–40 | 19–34 | 19–39 |
| Height (cm) | |||
| Mean (SD) | 175.24 (8.22) | 172.83 (8.11) | 176.50 (8.58) |
| Range | 158.2–188.6 | 161.0–194.5 | 163.2–190.0 |
| Weight (kg) | |||
| Mean (SD) | 72.75 (10.38) | 70.48 (10.42) | 75.25 (10.55) |
| Range | 57.8–92.7 | 57.9–94.6 | 61.4–103.6 |
| BMIa (kg/m2) | |||
| Mean (SD) | 23.56 (2.24) | 23.53 (2.69) | 24.15 (2.60) |
| Range | 20.0–28.2 | 19.4–28.1 | 19.4–29.6 |
| Neutralizing antibody titer prior to RSV inoculationb | |||
| Median | 810 | 1107 | 810 |
| Range | 156–1403 | 270–4209 | 270–4209 |
a
BMI, body mass index.
b
RSV neutralizing antibody titers were measured during screening, and only subjects with a value ≤810 were enrolled. Titers were measured again prior to RSV inoculation, and these values are reported here.